Sinaptica Therapeutics is one of the stronger emerging companies in dementia neuromodulation, using closed-loop rTMS-EEG to target default mode network dysfunction with growing clinical evidence. Its network-guided approach is more sophisticated than fixed-protocol stimulation systems, giving it a credible precision-therapy angle.